Sangamo Therapeutics Receives Nasdaq Delisting Notice; Trading Suspension Imminent

summarizeSummary

Sangamo Therapeutics received a formal delisting notice from Nasdaq, with trading of its common stock to be suspended on May 5, 2026, and will subsequently move to the OTCQB Venture Market.

check_boxKey Events

• Nasdaq Delisting Notice Received

  The company received a written notification from Nasdaq on April 28, 2026, stating its determination to delist the common stock due to ongoing non-compliance with the minimum bid price requirement.

• Trading Suspension Imminent

  Trading in Sangamo Therapeutics' common stock on The Nasdaq Capital Market will be suspended at the open of trading on May 5, 2026.

• Transition to OTCQB Market

  The company has received approval for its common stock to be quoted on the OTCQB Venture Market, with trading expected to commence on May 5, 2026, under its existing symbol 'SGMO'.

• Appeal Will Not Stay Suspension

  While the company plans to request a hearing to appeal the delisting determination, a timely request will stay the delisting but will not prevent the trading suspension.

auto_awesomeAnalysis

Sangamo Therapeutics has received a formal delisting notice from Nasdaq due to its failure to meet the minimum bid price requirement. This action formalizes a risk previously disclosed in the company's recent 10-K, which also included a going concern warning and limited cash runway. The imminent suspension of trading on Nasdaq and subsequent move to the OTCQB Venture Market typically results in reduced liquidity and diminished institutional investor interest, further complicating the company's efforts to raise capital and operate. While the company plans to appeal, this will not prevent the trading suspension, highlighting the severe challenges it faces, especially while trading near its 52-week low.